Weight loss and brain scans: why the new cohort does not prove cognitive protection
The full paper tells a more cautious story than its abstract: the key brain-volume comparison did not survive multiple-testing correction.
Search explainers, questions, and medicine profiles.
The publication’s independent editorial identity, covering weight-management research, treatments and practical strategies. No individual clinician or professional credential is claimed.
How we workMyWeightLab is an independent, evidence-first publication following GLP-1 medicines, obesity-drug research and the practical science of weight management.
This is a publication byline, not a clinician credential. Our articles do not provide diagnosis, prescriptions or individual treatment advice.
We check regulatory documents, trial registries, prescribing information and peer-reviewed research. Trial design, reported results and marketing approval are separate facts. Sponsor announcements are identified as such.
Editorial source review is distinct from independent clinical review. A real reviewer is credited only when their identity and contribution have been verified.
The full paper tells a more cautious story than its abstract: the key brain-volume comparison did not survive multiple-testing correction.
A new review highlights metabolic improvement in PCOS, but trial endpoints and selected responders limit what can be inferred about fertility.
A new review connects metabolic medicines with tumor biology, but the gap between an animal experiment and better cancer care remains substantial.
A focused subgroup estimate helps fill an evidence gap, but cannot predict individual weight loss or prove fewer cardiovascular events.
The STARKIDS study separates an early weight-development benefit from the challenge of sustaining support in everyday pediatric care.
The study adds viruses to the FMT research picture, while leaving causation and clinical usefulness unresolved.
The 25% headline depends on an idealized treatment scenario, while reproductive stage was assigned after the trial.
A large cancer-center study links weight-loss episodes with illness trajectories, but its prediction models remain a research finding.
A study of 8,127 women offers evidence about remote treatment delivery, with important limits on comparisons and promises.
A 68-week payer analysis illustrates why economic value differs from clinical benefit—and why its methods need closer scrutiny.